September 12, 2022 Media Coverage from ARCH Venture Partners | Share Freshly baked: ARCH-backed Pretzel Therapeutics takes out the oven mitts to drug diseases in the powerhouse of the cell, Jay Parrish leads company as CEO and Chairman
September 7, 2022 Media Coverage from ARCH Venture Partners | Share In Orbit: New ARCH-backed, Beam-buoyed biotech takes flight, gravitating toward the flash of RNA starlight
August 29, 2022 Media Coverage from ARCH Venture Partners | Share David Baker’s lab and ARCH sprout Lord of the Rings-inspired macrocycle biotech
August 2, 2022 Media Coverage from ARCH Venture Partners | Share BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-related biotech, with ARCH jumping in
June 29, 2022 Media Coverage from ARCH Venture Partners | Share ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn
June 29, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces $2.975 Billion Fund XII to Create and Fund Early Stage Biotechnology Companies
June 7, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Promotions and New Appointment
June 6, 2022 Media Coverage from ARCH Venture Partners | Share ARCH-backed Resilience nabs its latest financing round, putting together a massive $625M Series D
May 19, 2022 Portfolio News from ARCH Venture Partners | Share Bob Nelsen-founded Resilience inks manufacturing pact with ARCH-backed Be Bio
May 16, 2022 Media Coverage from ARCH Venture Partners | Share John Maraganore named on Fierce’s Most Influential People in BioPharma list
May 9, 2022 Media Coverage from ARCH Venture Partners | Share John Maraganore’s “Reflections on Alnylam,” published in Nature Biotech
April 26, 2022 Portfolio News from ARCH Venture Partners | Share Irv Weissman’s lab spins out Pheast Therapeutics to target new ‘don’t eat me’ signal, $76M Series A led by ARCH Venture
